Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:1.16.3.1 (ceruloplasmin)
5,074 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Plasma concentrations of various physiologically important proteins, including transferrin, ceruloplasmin, haptoglobin, transcortin, sex hormone-binding globulin, thyroxin-binding globulin, renin-substrate, fibrinogen, coagulation factors VII and VIII, antithrombin-III, plasminogen, prealbumin, albumin, retinol-binding protein, and lipoprotein fractions, were measured before treatment with oral contraceptives (OCs) and then again after 6 cycles of treatment to measure changes in the daily synthesis rate of 2 proteins, albumin and fibrinogen, under the influence of various OC formulations. Results are presented for 38 women using high-dose (50 mcg estrogen) preparations, 38 using low-dose (30 mcg estrogen preparations), and 20 using a continuous-dose progestagen-only minipill (30 mcg levonorgestrel). Most of the proteins measured showed significant alterations in women using the high-dose OCs. Changes with the lower dose product were less marked, and most proteins were unchanged in women using the minipill. (For example, synthesis rates of fibrinogen, mg/kg/day, for controls, high-, low-, and mini-dose subjects were: 24, 43, 28, and 25 respectively). Data from isotope studies indicated that synthetic estrogens act on liver synthesis and secretion rates for many plasma proteins; hence the clinical associations seen with OC use.
...
PMID:Oral contraceptives and plasma protein metabolism. 22 92

2 studies, A and B, were conducted to determine the metabolic effects of oral contraceptives (OCs). The subjects were healthy nonsmokers (17 to 27 years old, 1.52 m. to 1.75 m. in height, and 50 kg. to 60 kg. in weight) who were not undergoing any therapy. Controls did not have any previous history of hormonal therapy. In Study A, biochemical data from 17 women who were not on OCs were compared with those of women taking pills containing either 30 ug of ethinyl estradiol (EE) and 150 ug of D. norgestrel (18 women) or 50 ug. of EE and 250 ug. of D. norgestrel (9 women). In Study B, 8 women were studied before and during 3 to 4 cycles of low-dosed OC therapy (30 ug. of EE and 150 ug. of D. norgestrel). In both studies, the 2 oral contraceptive dosage forms had similar metabolic quantitative and qualitative changes: both resulted in an increase in serum concentration of triglycerides (30 to 33%), B-lipoproteins (27 to 29%), and ceruloplasmin (75 to 90%), and a decrease in serum levels of antithrombin 3 (22 to 29%) and ascorbic acid (30 to 42%). Serum cholesterol and phospholipid concentration did not change. The proportion of serum cholesterol carried by a-lipoproteins (high density lipoproteins) did decrease (the change is much smaller than that seen in coronary heart disease) while that carried by B-lipoproteins (or low density and very low density lipoproteins) increased. A significant negative correlation was observed between serum concentrations of ascorbic acid and cholesterol; this is interesting as clinical and experimental evidence suggests that latent ascorbic acid deficiency leads to hypercholesteroleamia, while ascorbic acid supplements reduce plasma cholesterol levels. As 500 mg. daily of ascorbic acid supplements supposedly help maintain normal ascorbic acid levels in blood during OC use, they should perhaps be prescribed to pill users in this study.
...
PMID:Metabolic effects of oral contraceptives containing 30 micrograms and 50 micrograms of oestrogen. 23 Apr 11

Blood coagulation factors, platelet function, fibrinolysis, and levels of plasma proteins were determined on 6 occasions during a single menstrual cycle in a group of women suffering from menorrhagia and in normally menstruating controls. Patients with menorrhagia had a slightly higher concentration of fibrinogen-fibrin degradation products, elevated factor 5 and 7 activity, increased antithrombin 3 and alpha(1)-antitrypsin concentrations, and higher antifibrinolytic activity than the control group. Subjects with menorrhagia also had lower concentrations of albumin, beta(IE)-globulin, orosomucoid, ceruloplasmin and IgG compared with controls. There was no marked difference in capillary fragility between the 2 groups. The differences in blood losses between the groups is not attributable to differences in clotting factors.
...
PMID:Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss. 100 35

We studied the effect of the plant alkaloid castanospermine on the biosynthesis and secretion of human hepatoma glycoproteins. The HepG-2 cells, grown in the presence or absence of the alkaloid, were labelled with [2-3H]mannose and then the labelled glycopeptides were prepared by Pronase digestion. This material was analysed by gel filtration on Bio-Gel P-4 before and after treatment with endo-beta-N-acetylglucosaminidase H. Castanospermine caused an accumulation of high-mannose oligosaccharides, by 70-75% over control. The major accumulated product, which could also be labelled with [3H]galactose and was only partially susceptible to alpha-mannosidase digestion, was identified by h.p.l.c. as a Glc3Man9GlcNAc. Thus the alkaloid inhibits glucosidase I in the human hepatoma cells. Analysis of total glycoproteins secreted by the cells into the medium revealed the presence of only complex oligosaccharides in both control and treated cultures, and the amount of the oligosaccharides labelled with radioactive mannose, galactose or N-acetylmannosamine, secreted by treated cells, was decreased by about 60%. The rate of secretion of total protein labelled with [35S]methionine and precipitated from the medium with trichloroacetic acid was inhibited by up to 40% in the presence of castanospermine. Pulse-chase studies utilizing [35S]methionine labelling were performed to study the effect of the alkaloid on secretion of individual plasma proteins. Immunoprecipitation at different chase times with monospecific antisera showed that castanospermine markedly decreased the secretion rates of alpha 1-antitrypsin, caeruloplasmin and, to a lesser extent, that of antithrombin-III. Secretions of apolipoprotein E, a glycoprotein containing only O-linked oligosaccharide(s), and albumin, a non-glycosylated protein, were not affected by the drug. It is suggested that castanospermine inhibits secretion of at least some glycoproteins containing N-linked oligosaccharides, owing to the inhibition of oligosaccharide processing.
...
PMID:Castanospermine inhibits glucosidase I and glycoprotein secretion in human hepatoma cells. 300 19

The amounts of total protein, albumin, fibronectin, alpha 2-macroglobulin (alpha 2-M), immunoglobulin G, ceruloplasmin and antithrombin were determined in fluids collected from 53 preovulatory equine follicles and compared with the contents of estradiol-17 beta, progesterone and androstenedione, with follicle size and the amounts of the equivalent proteins in normal equine plasma. The concentration of fibronectin and the fibronectin/albumin ratios increased significantly with follicle size and with follicular estradiol levels. The alpha 2-M levels and alpha 2-M/albumin ratios correlated with follicle size but not with hormone content. Both fibronectin and alpha 2-M were present in lower amounts in follicular fluid compared with plasma while the other proteins were present in similar amounts. Among the proteins evaluated, there was a positive correlation between the amount of the protein in the follicular fluid and the molecular weight of the protein.
...
PMID:Fibronectin concentrations correlate with ovarian follicular size and estradiol values in equine follicular fluid. 922 15

This study was designed to evaluate the amounts of coagulation factors and to determine whether the protein profile in pre-ovulatory ovarian follicular fluid aspirated from ovaries collected from mares at slaughter are representative of that in follicular fluid collected from live animals. The proteins evaluated included, (i) albumin, ceruloplasmin and fibronectin, (ii) the procoagulant plasma proteins, Factor V (FV), Factor VII (FVII), Factor X (FX) and prothrombin, and (iii) the anticoagulant plasma proteins, antithrombin and alpha2-macroglobulin. The amounts of the individual proteins were similar in both types of follicular fluid. There was no correlation between the activity of FV, FVII, FX or prothrombin in follicular fluid and their molecular size although a correlation was found for the other proteins. These results suggest that the procoagulant proteins in follicular fluid are not likely derived from plasma. The total protein content of follicular fluid samples collected from both sources was similar and the results determined with the Biuret, Lowry and Biorad methods were also not significantly different (P>0.05).
...
PMID:Amounts of selected coagulation factors in pre- and post-mortem follicular fluid are similar and do not correlate with molecular mass. 1098 28

Transgenic mice expressing the Simian virus 40 large T antigen under the control of the liver-specific human antithrombin-III promoter all develop well-differentiated hepatocellular carcinoma. During tumour development serum ceruloplasmin (Cp) increases gradually until it reaches 30 times control levels in all transgenic mice at 6 months of age. The accumulation of Cp in the serum is due to the increased transcription of the Cp gene as well as to the increase in Cp mRNA stability in the livers of the transgenic mice. One-half of the overproduced Cp is charged with copper and Cp-associated serum oxidase activity increases in parallel with the holo-Cp concentration. Through its ferroxidase activity Cp is involved prominently in iron metabolism. Analysis of copper and iron in serum and liver revealed increased copper levels in the serum of tumour-bearing animals and which increased in parallel with Cp concentration; the amounts of copper in the liver were unchanged. In contrast, serum iron remained constant during tumour development whereas the iron concentration in the livers of the transgenic mice decreased.
...
PMID:High levels of ceruloplasmin in the serum of transgenic mice developing hepatocellular carcinoma. 1123 3

We used plasma proteomics to identify human proteins responsive to folate status. Plasma was collected from subjects treated with placebo or 1.2 mg of folic acid daily for 12 weeks in a randomized controlled trial. Homocysteine and folate were measured by immunoassay and uracil misincorporation by electrophoresis. The plasma proteome was assessed by 2-D gel electrophoresis, and proteins were identified by LC MS/MS. 5-methylTHF increased 5-fold (P = 0.000003) in response to intervention. Red cell folate doubled (P = 0.013), and lymphocyte folate increased 44% (P = 0.0001). Hcy and uracil dropped 22% (P = 0.0005) and 25% (P = 0.05), respectively. ApoE A-1, alpha-1-antichymotrypsin, antithrombin, and serum amyloid P were downregulated, while albumin, IgM C, and complement C3 were upregulated (P < 0.05). More than 60 proteins were significantly associated with folate pre- and postintervention (P < 0.01). These were categorized into metabolic pathways related to complement fixation (e.g., C1, C3, C4, Factor H, Factor 1, Factor B, clusterin), coagulation (e.g., antithrombin, alpha-1-antitrypsin, kininogen) and mineral transport (e.g., transthyretin, haptoglobin, ceruloplasmin). Low folate status pre- and post-treatment were associated with lower levels of proteins involved in activation and regulation of immune function and coagulation. Supplementation with synthetic folic acid increased expression of these proteins but did not substantially disrupt the balance of these pathways.
...
PMID:Blood folate status and expression of proteins involved in immune function, inflammation, and coagulation: biochemical and proteomic changes in the plasma of humans in response to long-term synthetic folic acid supplementation. 2014 72

Acute phase reaction is a systemic response which usually follows a physiological condition that takes place in the beginning of an inflammatory process. This physiological change usually lasts 1-2 days. However, the systemic acute phase response usually lasts longer. The aim of this systemic response is to restore homeostasis. These events are accompanied by upregulation of some proteins (positive acute phase reactants) and downregulation of others (negative acute phase reactants) during inflammatory reactions. Cardiovascular diseases are accompanied by the elevation of several positive acute phase reactants such as C-reactive protein (CRP), serum amyloid A (SAA), fibrinogen, white blood cell count, secretory nonpancreatic phospholipase 2-II (sPLA2-II), ferritin, and ceruloplasmin. Cardiovascular disease is also accompanied by the reduction of negative acute phase reactants such as albumin, transferrin, transthyretin, retinol-binding protein, antithrombin, and transcortin. In this paper, we will be discussing the biological activity and diagnostic and prognostic values of acute phase reactants with cardiovascular importance. The potential therapeutic targets of these reactants will be also discussed.
...
PMID:Acute phase reactants as novel predictors of cardiovascular disease. 2404 53

Glycosylation is the most abundant and complex protein modification, and can have a profound structural and functional effect on the conjugate. The oligosaccharide fraction is recognized to be involved in multiple biological processes, and to affect proteins physical properties, and has consequentially been labeled a critical quality attribute of biopharmaceuticals. Additionally, due to recent advances in analytical methods and analysis software, glycosylation is targeted in the search for disease biomarkers for early diagnosis and patient stratification. Biofluids such as saliva, serum or plasma are of great use in this regard, as they are easily accessible and can provide relevant glycosylation information. Thus, as the assessment of protein glycosylation is becoming a major element in clinical and biopharmaceutical research, this review aims to convey the current state of knowledge on the N-glycosylation of the major plasma glycoproteins alpha-1-acid glycoprotein, alpha-1-antitrypsin, alpha-1B-glycoprotein, alpha-2-HS-glycoprotein, alpha-2-macroglobulin, antithrombin-III, apolipoprotein B-100, apolipoprotein D, apolipoprotein F, beta-2-glycoprotein 1, ceruloplasmin, fibrinogen, immunoglobulin (Ig) A, IgG, IgM, haptoglobin, hemopexin, histidine-rich glycoprotein, kininogen-1, serotransferrin, vitronectin, and zinc-alpha-2-glycoprotein. In addition, the less abundant immunoglobulins D and E are included because of their major relevance in immunology and biopharmaceutical research. Where available, the glycosylation is described in a site-specific manner. In the discussion, we put the glycosylation of individual proteins into perspective and speculate how the individual proteins may contribute to a total plasma N-glycosylation profile determined at the released glycan level.
...
PMID:Human plasma protein N-glycosylation. 2655 91


1 2 Next >>

---